business combination shall have occurred (the “Extension Payment”) in exchange for a non-interest bearing, unsecured promissory note payable upon consummation of a business combination and (ii) the procedures relating to any such extension, as set forth in the Trust Agreement, shall have been complied with;
•
a proposal to amend the Company’s investment management trust agreement, dated as of May 27, 2021 (the “Trust Agreement”), by and between the Company and Continental Stock Transfer & Trust Company (the “Trustee”), allowing the Company to extend the Termination Date for an additional six one (1) month extensions until June 2, 2023 (the “Trust Amendment”), by depositing into the Trust Account $125,000 for each such one-month extension until June 2, 2023 unless the Closing of the Company’s initial business combination shall have occurred, referenced herein as the Extension Payment for such extension, which we refer to as the “Trust Amendment Proposal”; and
•
a proposal to approve the adjournment of the Special Meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of the Extension Amendment Proposal, which we refer to as the “Adjournment Proposal.” The Adjournment Proposal will only be presented at the Special Meeting if there are not sufficient votes to approve the Extension Amendment Proposal.
Each of the Extension Amendment Proposal, the Trust Amendment Proposal and the Adjournment Proposal is more fully described in the accompanying Proxy Statement.
The purpose of the Extension Amendment Proposal, the Trust Amendment Proposal and, if necessary, the Adjournment Proposal, is to allow us additional time to complete the Initial Business Combination (“Business Combination”). The Company’s IPO prospectus and the Existing Charter provide that the Company has until the Termination Date to complete a Business Combination. While we had entered into Agreement and Plan of Merger, dated as of August 10, 2022 (the “Business Combination Agreement”), with Captura Biopharma, Inc., a Delaware corporation (“Captura”), on October 13, 2022, we entered into that certain Mutual Termination Agreement (the “Termination Agreement”) pursuant to which OceanTech and Captura mutually agreed to terminate the Business Combination Agreement pursuant to Section 8.1(a) thereof. For more information about the Termination Agreement, see our Current Reports on Form 8-K filed with the U.S. Securities and Exchange Commission (the “SEC”) on October 14, 2022.
While we are using our best efforts to enter into and complete a new Business Combination as soon as practicable, our board of directors (the “Board”) believes that there will not be sufficient time before the Termination Date to to enter into a new Business Combination Agreement and hold a general meeting at which to conduct a vote for shareholder approval of the Business Combination. Accordingly, the Board believes that in order to be able to consummate the Business Combination, we will need to obtain the Extension. Without the Extension, the Board believes that there is significant risk that we might not, despite our best efforts, be able to enter into and complete the Business Combination on or before the Termination Date. If that were to occur, we would be precluded from completing the Business Combination and would be forced to liquidate even if our stockholders are otherwise in favor of consummating the Business Combination.
The purpose of the Extension Amendment and the Trust Amendment Proposal is to allow the Company more time to enter into and complete the Business Combination. In addition, we will not proceed with the Extension if the number of redemptions or repurchases of our shares of Class A common stock issued in our IPO, which shares we refer to as the “public shares,” exceeds 8,862,585 shares (or 86% redemptions) or causes us to have less than $5,000,001 of net tangible assets following approval of the Extension Amendment Proposal.
If the Extension is approved and implemented, subject to satisfaction of the conditions to closing in the Business Combination (including, without limitation, receipt of stockholder approval of the Business Combination), we intend to complete the Business Combination as soon as possible and in any event on or before the Extended Date.
In connection with the Extension Amendment Proposal, public stockholders may elect to redeem their public shares for a per-share price, payable in cash, equal to the aggregate amount then on deposit in the trust account (the “Trust Account”), including interest (which interest shall be net of taxes payable), divided